PURPOSE: We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC). METHODS: A series of 25 lung cancer cell lines were evaluated for Foxa2 protein expression, FOXA2 mRNA levels, FOXA2 mutations, FOXA2 copy number changes and for evidence of FOXA2 promoter hypermethylation. In addition, 32 NSCLCs were sequenced for FOXA2 mutations and 173 primary NSCLC tumors evaluated for Foxa2 expression using an immunohistochemical assay. RESULTS: Out of the 25 cell lines, 13 (52%) had undetectable FOXA2 mRNA. The expression of FOXA2 mRNA and Foxa2 protein were congruent in 19/22 cells (p = 0.001). FOXA2 mutations were not identified in primary NSCLCs and were infrequent in cell lines. Focal or broad chromosomal deletions involving FOXA2 were not present. The promoter region of FOXA2 had evidence of hypermethylation, with an inverse correlation between FOXA2 mRNA expression and presence of CpG dinucleotide methylation (p < 0.0001). In primary NSCLC tumor specimens, there was a high frequency of either absence (42/173, 24.2%) or no/low expression (96/173, 55.4%) of Foxa2. In 130 patients with stage I NSCLC there was a trend towards decreased survival in tumors with no/low expression of Foxa2 (HR of 1.6, 95%CI 0.9-3.1; p = 0.122). CONCLUSIONS: Loss of expression of Foxa2 is frequent in lung cancer cell lines and NSCLCs. The main mechanism of downregulation of Foxa2 is epigenetic silencing through promoter hypermethylation. Further elucidation of the involvement of Foxa2 and other airway transcription factors in the pathogenesis of lung cancer may identify novel therapeutic targets.
PURPOSE: We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC). METHODS: A series of 25 lung cancer cell lines were evaluated for Foxa2 protein expression, FOXA2 mRNA levels, FOXA2 mutations, FOXA2 copy number changes and for evidence of FOXA2 promoter hypermethylation. In addition, 32 NSCLCs were sequenced for FOXA2 mutations and 173 primary NSCLC tumors evaluated for Foxa2 expression using an immunohistochemical assay. RESULTS: Out of the 25 cell lines, 13 (52%) had undetectable FOXA2 mRNA. The expression of FOXA2 mRNA and Foxa2 protein were congruent in 19/22 cells (p = 0.001). FOXA2 mutations were not identified in primary NSCLCs and were infrequent in cell lines. Focal or broad chromosomal deletions involving FOXA2 were not present. The promoter region of FOXA2 had evidence of hypermethylation, with an inverse correlation between FOXA2 mRNA expression and presence of CpG dinucleotide methylation (p < 0.0001). In primary NSCLC tumor specimens, there was a high frequency of either absence (42/173, 24.2%) or no/low expression (96/173, 55.4%) of Foxa2. In 130 patients with stage I NSCLC there was a trend towards decreased survival in tumors with no/low expression of Foxa2 (HR of 1.6, 95%CI 0.9-3.1; p = 0.122). CONCLUSIONS: Loss of expression of Foxa2 is frequent in lung cancer cell lines and NSCLCs. The main mechanism of downregulation of Foxa2 is epigenetic silencing through promoter hypermethylation. Further elucidation of the involvement of Foxa2 and other airway transcription factors in the pathogenesis of lung cancer may identify novel therapeutic targets.
Authors: Daniel B Costa; Tajhal Dayaram; Francesco D'Alo; Bas J Wouters; Daniel G Tenen; Matthew Meyerson; Ming-Sound Tsao; Balazs Halmos Journal: Lung Cancer Date: 2006-06-12 Impact factor: 5.705
Authors: Yasuhiro Tada; Romulo Martin Brena; Björn Hackanson; Carl Morrison; Gregory A Otterson; Christoph Plass Journal: J Natl Cancer Inst Date: 2006-03-15 Impact factor: 13.506
Authors: Daniel B Costa; Sigui Li; Olivier Kocher; Richard H Feins; Steven M Keller; Joan H Schiller; David H Johnson; Daniel G Tenen; Balazs Halmos Journal: Lung Cancer Date: 2007-01-18 Impact factor: 5.705
Authors: Barbara A Weir; Michele S Woo; Gad Getz; Sven Perner; Li Ding; Rameen Beroukhim; William M Lin; Michael A Province; Aldi Kraja; Laura A Johnson; Kinjal Shah; Mitsuo Sato; Roman K Thomas; Justine A Barletta; Ingrid B Borecki; Stephen Broderick; Andrew C Chang; Derek Y Chiang; Lucian R Chirieac; Jeonghee Cho; Yoshitaka Fujii; Adi F Gazdar; Thomas Giordano; Heidi Greulich; Megan Hanna; Bruce E Johnson; Mark G Kris; Alex Lash; Ling Lin; Neal Lindeman; Elaine R Mardis; John D McPherson; John D Minna; Margaret B Morgan; Mark Nadel; Mark B Orringer; John R Osborne; Brad Ozenberger; Alex H Ramos; James Robinson; Jack A Roth; Valerie Rusch; Hidefumi Sasaki; Frances Shepherd; Carrie Sougnez; Margaret R Spitz; Ming-Sound Tsao; David Twomey; Roel G W Verhaak; George M Weinstock; David A Wheeler; Wendy Winckler; Akihiko Yoshizawa; Soyoung Yu; Maureen F Zakowski; Qunyuan Zhang; David G Beer; Ignacio I Wistuba; Mark A Watson; Levi A Garraway; Marc Ladanyi; William D Travis; William Pao; Mark A Rubin; Stacey B Gabriel; Richard A Gibbs; Harold E Varmus; Richard K Wilson; Eric S Lander; Matthew Meyerson Journal: Nature Date: 2007-11-04 Impact factor: 49.962
Authors: Tibor A Rauch; Xueyan Zhong; Xiwei Wu; Melody Wang; Kemp H Kernstine; Zunde Wang; Arthur D Riggs; Gerd P Pfeifer Journal: Proc Natl Acad Sci U S A Date: 2007-12-27 Impact factor: 11.205
Authors: D J Kwiatkowski; D H Harpole; J Godleski; J E Herndon; D B Shieh; W Richards; R Blanco; H J Xu; G M Strauss; D J Sugarbaker Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544
Authors: Daniel B Costa; Balázs Halmos; Amit Kumar; Susan T Schumer; Mark S Huberman; Titus J Boggon; Daniel G Tenen; Susumu Kobayashi Journal: PLoS Med Date: 2007-10 Impact factor: 11.069
Authors: B Smith; R Neff; D E Cohn; F J Backes; A A Suarez; D G Mutch; C M Rush; C J Walker; P J Goodfellow Journal: Gynecol Oncol Date: 2016-08-15 Impact factor: 5.482
Authors: Norihiro Yamaguchi; Antonio R Lucena-Araujo; Sohei Nakayama; Lorena L de Figueiredo-Pontes; David A Gonzalez; Hiroyuki Yasuda; Susumu Kobayashi; Daniel B Costa Journal: Lung Cancer Date: 2013-10-14 Impact factor: 5.705
Authors: J Song; I H Heijink; L E M Kistemaker; M Reinders-Luinge; W Kooistra; J A Noordhoek; R Gosens; C A Brandsma; W Timens; P S Hiemstra; M G Rots; M N Hylkema Journal: Clin Epigenetics Date: 2017-04-24 Impact factor: 6.551
Authors: Paulo P Amaral; Tommaso Leonardi; Namshik Han; Emmanuelle Viré; Dennis K Gascoigne; Raúl Arias-Carrasco; Magdalena Büscher; Luca Pandolfini; Anda Zhang; Stefano Pluchino; Vinicius Maracaja-Coutinho; Helder I Nakaya; Martin Hemberg; Ramin Shiekhattar; Anton J Enright; Tony Kouzarides Journal: Genome Biol Date: 2018-03-15 Impact factor: 13.583